A new study takes a close look at the content and potential implications of the new Texas law HB 810, which aims to expand assess of experimental stem cell interventions outside the realm of clinical trials under FDA oversight. HB 810 represents a new level of deregulation after the Right To Try laws and presents concerns including ambiguity over what constitutes a chronic illness, reporting requirements, and safety concerns, as described in an article in Stem Cells and Development.

Source link